Abstract:Background: Worldwide, it is projected that 285 million individuals have diabetes, and by 2030, this number is expected to climb to 438 million. About 90% of cases of diabetes mellitus are type 2 (T2DM). Insulin sensitizers, such as metformin and thiazolidinediones; insulin secretagogues, such as sulfonylureas and glinides; dipeptidyl peptidase 4 (DPP-4) inhibitors; glucosidase inhibitors, or oral combination therapy are currently available treatments for type 2 diabetes. Some of these drugs exhibit serious limitations; thus, it is crucial to design an innovative therapy that is efficient and depends on a new channel. Aim: In the current work, a stability-indicating reverse phase HPLC (RP-HPLC) technique was developed and subsequently validated for the detection of dapagliflozin in its API. Methods: The stability-indicating HPLC method for assay included the use of Kromasil 100-5-C8 (100 mm × 4.6 mm) column, UV detector 224 nm, mobile phase composition involving a mixture of acetonitrile:water (52:48), and a flow rate of 1.0 mL/min. ICH guidelines were followed for the method's validation. To assess the method's specificity and stability in showing characteristics, stress degradation studies were carried out. The working standard solution of dapagliflozin was exposed to 1 and 2 N HCl by refluxing 1 and 2 N NaOH with 30% hydrogen peroxide by volume and UV radiation in order to conduct a degradation study. Results: All system suitability parameters were determined to be within the intended ranges, and the drug's retention duration was discovered to be 1.67 minutes. It was also investigated as to how the drug degraded under various circumstances. The drug was discovered to be stable under situations of photolytic, thermal, neutral, alkaline, and oxidative deterioration. The developed stabilityindicating HPLC technique was validated in accordance with ICH Q2 recommendations, and the validation parameters, such as linearity, precision, and robustness, were achieved within the approved standards. Conclusion: It may be concluded that this method is stability-indicating and specific, and it can be successfully applied to analyze tablet dosage forms containing dapagliflozin.

Failure Mode Identification of Insulin Drug Products-Impact of Relevant Stress Conditions on the Quality of the Drug

A comprehensive stability assessment of insulin degludec using New customized validated RP-HPLC and SEC-HPLC methods in an orthogonal testing protocol

Identification and Characterization of Chemical and Physical Stability of Insulin Formulations Utilizing Degraded Glycerol after Repeated Use and Storage.

Elucidating the Degradation Pathways of Human Insulin in the Solid State

Insulin Stabilization Designs for Enhanced Therapeutic Efficacy and Accessibility

Forced Degradation Products of Liraglutide: A Comparative Study of Similarity Between Originator and Analogue Version by Liquid Chromatography–Mass Spectrometry

Stability and Diffusion Properties of Insulin in Dissolvable Microneedles: A Multiscale Simulation Study

Thermal stability of exenatide encapsulated in stratified dissolving microneedles during storage

Optimization of a Coupling Process for Insulin Degludec According to a Quality by Design (qbd) Paradigm

Stress Factors in Primary Packaging, Transportation and Handling of Protein Drug Products and Their Impact on Product Quality

High Throughput In-Use and Stress Size Stability Screening of Protein Therapeutics Using Algorithm-Driven Dynamic light scattering.

Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges

Self-Assembled, Dilution-Responsive Hydrogels for Enhanced Thermal Stability of Insulin Biopharmaceuticals

Drug Stability: ICH versus Accelerated Predictive Stability Studies

High-Voltage Leak Detection of a Parenteral Proteinaceous Solution Product Packaged in Form-Fill-Seal Plastic Laminate Bags. Part 3. Chemical Stability and Visual Appearance of a Protein-Based Aqueous Solution for Injection as a Function of HVLD Exposure

Analytical Method Development, Validation and Forced Degradation Study of Dapagliflozin by RP-HPLC

Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs

Regulatory Verification by Health Canada of Content in Recombinant Human Insulin, Human Insulin Analog, and Porcine Insulin Drug Products in the Canadian Market Using Validated Pharmacopoeial Methods Over Nonvalidated Approaches

Availability of Insulin From Parenteral Nutrient Solutions

Analysis of omarigliptin forced degradation products by ultra‐fast liquid chromatography, mass spectrometry, and in vitro toxicity assay

A comprehensive study on the identification and characterization of major degradation products of synthetic liraglutide using liquid chromatography‐high resolution mass spectrometry